Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS

    NEXT STORY
    Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    PREV STORY
    Oasmia ADSs delisted from NASDAQ in the US
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference

    author_avatar
    NASDAQ Market News

    Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

    -  In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an ...

    author_avatar
    NASDAQ Market News

    OMRF collaborates with GSK to develop novel treatments for severe inflammatory diseases

    OKLAHOMA CITY, July 24, 2017 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation (OMRF) ...

    author_avatar
    NASDAQ Market News